Journey Medical (DERM) Invested Capital (2020 - 2026)

Journey Medical has reported Invested Capital for 7 years, with the latest figure at $33.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 42.34% year-over-year to $33.3 million; the trailing twelve-month figure through Mar 2026 stood at $33.3 million (up 42.34% YoY), and the FY2025 full-year result was $31.9 million, down 29.14% from the prior year.
• Invested Capital for Q1 2026 stood at $33.3 million, up from $31.9 million in the prior quarter.
• The five-year high for Invested Capital was $56.2 million in Q1 2022, with the low at $9.9 million in Q2 2023.
• Historically, Invested Capital has averaged $33.3 million across 5 years, with a median of $31.5 million in 2025.
• Annual changes were most pronounced in 2022 — Invested Capital surged 6361.99% — and 2023, when it tumbled 79.94%.
• Journey Medical's Invested Capital stood at $44.7 million in 2022, then slipped by 21.85% to $35.0 million in 2023, then advanced by 28.53% to $44.9 million in 2024, then fell by 29.14% to $31.9 million in 2025, then rose by 4.64% to $33.3 million in 2026.
• The last three Invested Capital figures came in at $33.3 million (Q1 2026), $31.9 million (Q4 2025), and $31.5 million (Q3 2025), per Business Quant data.